CLS vs ROP

Celestica Inc. exhibits a stark divergence between its explosive growth metrics and its deterministic health indicators, highlighted by a weak Piotroski F-Score of 3/9. While the company delivers exceptional revenue (43.6%) and earnings (77.7%) growth with a consistent track record of beats, the current price of $410.21 represents a massive premium over both the Graham Number ($55.82) and the growth-based Intrinsic Value ($211.81). The combination of bearish insider selling and a weak technical trend suggests the stock may be overextended despite strong analyst sentiment. Consequently, the valuation risk currently outweighs the growth momentum.

ROP presents a compelling investment case despite near-term price underperformance, trading at a significant discount to its $573.87 analyst target price with strong fundamentals intact. The company demonstrates consistent earnings execution, beating estimates in 3 of the last 4 quarters and delivering double-digit YoY EPS growth of 11.3%, underpinned by best-in-class margins (68.96% gross, 28.40% operating). While insider selling raises caution, it appears opportunistic rather than strategic, and the stock remains deeply undervalued relative to both its growth trajectory and the broader technology sector’s sky-high valuation multiples. ROP’s disciplined capital allocation, low leverage, and durable software-driven business model position it well for re-rating as macro sentiment improves.